The Treatment of Relapsed Refractory Chronic Lymphocytic Leukemia

被引：35

作者：

Brown, Jennifer R. ^{[1
,2
]}

机构：

[1] Harvard Univ, Sch Med, Boston, MA 02215 USA

[2] Dana Farber Canc Inst, CLL Ctr, Boston, MA 02215 USA

来源：

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2011年

关键词：

STEM-CELL TRANSPLANTATION; HIGH-DOSE METHYLPREDNISOLONE; TERM-FOLLOW-UP; MARROW-TRANSPLANTATION; ALEMTUZUMAB CAMPATH-1H; CLINICAL-EFFICACY; EFFECTIVE THERAPY; SALVAGE THERAPY; POOR-PROGNOSIS; FLUDARABINE;

D O I：

10.1182/asheducation-2011.1.110

中图分类号：

G40 [教育学];

学科分类号：

040101 ; 120403 ;

摘要：

Despite the widespread use of highly effective chemoimmunotherapy (CIT), fludarabine-refractory chronic lymphocytic leukemia (CLL) remains a challenging clinical problem associated with poor overall survival (OS). The traditional definition, which includes those patients with no response or relapse within 6 months of fludarabine, is evolving with the recognition that even patients with longer remissions of up to several years after CIT have poor subsequent treatment response and survival. Approved therapeutic options for these patients remain limited, and the goal of therapy for physically fit patients is often to achieve adequate cytoreduction to proceed to allogeneic stem cell transplantation (alloSCT). Fortunately, several novel targeted therapeutics in clinical trials hold promise of significant benefit for this patient population. This review discusses the activity of available and novel therapeutics in fludarabine-refractory or fludarabine-resistant CLL as well as recently updated data on alloSCT in CLL.

引用

页码：110 / 118

页数：9

共 66 条

[11] Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study [J].

Byrd, J. C. ;

Blum, K. A. ;

Burger, J. A. ;

Coutre, S. E. ;

Sharman, J. P. ;

Furman, R. R. ;

Flinn, I. W. ;

Grant, B. W. ;

Richards, D. A. ;

Zhao, W. ;

Heerema, N. A. ;

Johnson, A. J. ;

Izumi, R. ;

Hamdy, A. ;

O'Brien, S. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[12] Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53 [J].

Byrd, JC ;

Shinn, C ;

Waselenko, JK ;

Fuchs, EJ ;

Lehman, TA ;

Nguyen, PL ;

Flinn, IW ;

Diehl, LF ;

Sausville, E ;

Grever, MR .

BLOOD, 1998, 92 (10) :3804-3816

[13] Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia [J].

Byrd, John C. ;

Lin, Thomas S. ;

Dalton, James T. ;

Wu, Di ;

Phelps, Mitch A. ;

Fischer, Beth ;

Moran, Mollie ;

Blum, Kristie A. ;

Rovin, Brad ;

Brooker-McEldowney, Michelle ;

Broering, Sarah ;

Schaaf, Larry J. ;

Johnson, Amy J. ;

Lucas, David M. ;

Heerema, Nyla A. ;

Lozanski, Gerard ;

Young, Donn C. ;

Suarez, Jose-Ramon ;

Colevas, A. Dimitrios ;

Grever, Michael R. .

BLOOD, 2007, 109 (02) :399-404

[14] Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia [J].

Castro, J. E. ;

Sandoval-Sus, J. D. ;

Bole, J. ;

Rassenti, L. ;

Kipps, T. J. .

LEUKEMIA, 2008, 22 (11) :2048-2053

[15] Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study [J].

Chanan-Khan, Asher ;

Miller, Kena C. ;

Musial, Laurie ;

Lawrence, David ;

Padmanabhan, Swaminathan ;

Takeshita, Kenichi ;

Porter, Carl W. ;

Goodrich, David W. ;

Bernstein, Zale P. ;

Wallace, Paul ;

Spaner, David ;

Mohr, Alice ;

Byrne, Catriona ;

Hernandez-Ilizaliturri, Francisco ;

Chrystal, Cynthia ;

Starostik, Petr ;

Czuczman, Myron S. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5343-5349

[16]

Chanan-Khan AA, 2007, BLOOD, V110, p1057A

[17] Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. [J].

Coutre, S. E. ;

Byrd, J. C. ;

Furman, R. R. ;

Brown, J. R. ;

Benson, D. M. ;

Wagner-Johnston, N. D. ;

Flinn, I. W. ;

Kahl, B. S. ;

Spurgeon, S. E. F. ;

Lannutti, B. J. ;

Hsu, H. K. W. ;

Ulrich, R. ;

Peterman, S. ;

Holes, L. ;

Miller, L. L. ;

Yu, A. S. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[18] Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis [J].

Delgado, J. ;

Pillai, S. ;

Phillips, N. ;

Brunet, S. ;

Pratt, G. ;

Briones, J. ;

Lovell, R. ;

Martino, R. ;

Ewing, J. ;

Sureda, A. ;

Milligan, D. W. ;

Sierra, J. .

ANNALS OF ONCOLOGY, 2009, 20 (12) :2007-2012

[19] Genomic aberrations and survival in chronic lymphocytic leukemia. [J].

Döhner, H ;

Stilgenbauer, S ;

Benner, A ;

Leupolt, E ;

Kröber, A ;

Bullinger, L ;

Döhner, K ;

Bentz, M ;

Lichter, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) :1910-1916

[20] Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus [J].

Dreger, P. ;

Corradini, P. ;

Kimby, E. ;

Michallet, M. ;

Milligan, D. ;

Schetelig, J. ;

Wiktor-Jedrzejczak, W. ;

Niederwieser, D. ;

Hallek, M. ;

Montserrat, E. .

LEUKEMIA, 2007, 21 (01) :12-17

← 1 2 3 4 5 6 7 →